Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$56.09
-0.3%
$49.63
$30.04
$71.13
$4.86B1.83.67 million shs2.99 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$77.76
-0.8%
$78.69
$55.53
$113.51
$5.63B1.3463,959 shs376,599 shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$19.53
-3.9%
$21.75
$16.60
$28.47
$1.49B1.67942,510 shs1.12 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$35.02
-1.4%
$36.83
$16.65
$46.48
$5.64B1.951.51 million shs2.32 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-0.30%-13.39%+8.55%+46.64%-2.09%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-0.75%-4.48%-3.40%+0.39%-2.73%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-3.94%-12.15%-6.82%-22.78%-12.34%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
-1.35%-5.09%-3.50%-19.38%+77.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.7909 of 5 stars
3.32.00.00.03.03.30.6
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.2027 of 5 stars
4.51.00.00.02.83.30.0
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.5882 of 5 stars
3.42.00.00.03.41.70.6
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
4.0843 of 5 stars
3.40.00.03.52.92.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.50
Moderate Buy$70.0724.92% Upside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
3.09
Buy$119.6053.81% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.75
Moderate Buy$32.7567.69% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.80
Moderate Buy$43.8025.07% Upside

Current Analyst Ratings Breakdown

Latest SDGR, TGTX, NUVL, and CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$79.00 ➝ $78.00
7/21/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$115.00
7/14/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$32.00 ➝ $30.00
7/10/2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$37.00
7/8/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
7/3/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$28.00
6/30/2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$86.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.31M129.83N/AN/A$22.64 per share2.48
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$14.99 per shareN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$207.54M6.91N/AN/A$5.78 per share3.38
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$329M16.90$0.12 per share295.93$1.43 per share24.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$260.76M-$4.39N/AN/AN/AN/A-31.35%-29.27%8/14/2025 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%8/6/2025 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$23.38M$0.24145.9235.02N/A10.13%18.88%7.05%8/4/2025 (Estimated)

Latest SDGR, TGTX, NUVL, and CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.27N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.83N/AN/AN/A$52.03 millionN/A
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.54N/AN/AN/A$6.44 millionN/A
8/4/2025Q2 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.27N/AN/AN/A$147.76 millionN/A
5/8/2025Q1 2025
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.14-$1.18-$0.04-$1.18N/AN/A
5/7/2025Q1 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
5/7/2025Q1 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.19$0.03-$0.16$0.03$117.07 million$120.86 million
5/6/2025Q1 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.27-$1.58-$0.31-$1.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
15.64
15.64
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
14.48
14.48
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.45
3.45
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.03
4.02
3.04

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.30%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10.20%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
8.60%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
10.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46086.36 million82.65 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4071.81 million64.48 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.38 million67.07 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.76 million141.86 millionOptionable

Recent News About These Companies

TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday
The Play On TG Therapeutics
TG Therapeutics (TGTX) Gets a Hold from Goldman Sachs

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$56.09 -0.17 (-0.30%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$56.14 +0.05 (+0.09%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$77.76 -0.59 (-0.75%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$77.76 -0.01 (-0.01%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$19.53 -0.80 (-3.94%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$19.80 +0.27 (+1.38%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$35.02 -0.48 (-1.35%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$35.33 +0.31 (+0.87%)
As of 08/1/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.